A Judicial Panel on Multidistrict Litigation consolidated 13 insulin price-fixing lawsuits and future tag-along cases from states, counties and private entities against three of the largest pharmaceutical companies in the world, who face allegations of over-inflating prices of the insulin they manufacture.

Attorneys from two Florida firms are among the dozens of lawyers positioned to continue the litigation, which could have a far-reaching impact throughout the U.S., where more than 130 million adults are living with diabetes or prediabetes, according to the Centers for Disease Control and Prevention.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]